Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

On Saturday afternoon, Barclays' website indicated that problems persisted with its app, and warned that customers may face issues making and receiving payments. The website also told customers ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...

this represents a significant step into the gene therapy space for Vertex. 3. VX-548 for Chronic Pain: Investors are eagerly awaiting Phase 2 data for VX-548 in low back pain (LSR), expected by ...

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

As markets await the presentation of the government budget over the weekend, the Indian rupee is predicted to open lower on Friday, perhaps plunging to a lifetime low due to the threat of tariffs ...